Inverness carries on along acquisition trail
This article was originally published in Clinica
Executive Summary
Inverness Medical Innovations has entered an acquisition agreement with protein-based diagnostics specialist Matritech that will see it clinch its sixth purchase of the year. The Matritech buy, expected to close in the fourth quarter of 2007, will cost Inverness $36m in common stock, possibly highlighting that such prolific purchases have taken their toll on the company's financial reserves.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continue, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.